 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2014, vol. 20, issue 1
Subject Collection: Oral and Dental Medicine
Pages: 464-468
DOI: 10.5272/jimab.2014201.464
Published online: 10 March 2014
J of IMAB 2014 Jan-Jun;20(1):464-468
AZITHROMYCIN DECREASE SALIVA CALPROTECTIN IN PATIENTS WITH PERIODONTAL DISEASES.
Vladimir E. Panov,1 Assya Krasteva2 
, Adriana Z. Krasteva3, Aneta Ivanova4, Anton Panov5, Zahariy Krastev4.
1) Department of Conservative dentistry and oral pathology, Faculty of Dental Medicine, Medical University Varna, Bulgaria
2) Department of Diagnostic Imaging and Oral diagnostic, Faculty of Dental medicine, Medical University, Sofia, Bulgaria
3) Department of Pharmacology and Toxicology, Faculty of Pharmacy, Medical University - Sofia, Bulgaria
4) Clinic of Gastroenterology, University Hospital "St. Ivan Rilski", Sofia, Bulgaria
5) Dentist. Private practice, Sofia, Bulgaria.
ABSTRACT:
Objective: Calprotectin is a calcium binding heterocomplex protein which appear to have regulatory functions in the inflammatory process. Epithelial cells which expressing calprotectin are more resistant to bacterial invasion . In acute phase inflammatory reactions calprotectin is detectable in elevated levels.
The aim of the present study is to detect the calprotectin level in saliva in patients with periodontal disease (chronic and aggressive periodontitis and gingivitis) and to follow calprotectin level during azithromycin treatment.
Methods and materials: In nine healthy patients without systemic disease and malignancy whole unstimulated saliva was investigated. Salivary calprotectin levels were measured by enzyme-linked-immunosorbent using a commercial kit (ELISA Hycult Biotech). Azithromycin treatment was taken as 500 mg (2 x 250 mg tabls.) once daily at 10.00 am for 4 consecutive days.
Results: At baseline Day levels of calprotectin ranged between 1.45 and 2.97; median 2.19. On Day 5 (first day after azithromycin treatment) the salivary calprotectin levels decreased in 6 of the patients. The measured values at Day 10 were more similar to those at Day 5, than those at Day zero. This was confirmed by the values of the average median of calprotectin.
Conclusion: We present the first study with the application of antibiotic and measurement the calprotectin levels before, during and after azithromycin intake with no side effects reported.
Measuring calprotectin levels could benefit the monitoring of antibiotic treatment efficacy in patients with gingivitis and periodontitis.
Key words: calprotectin; saliva; periodontal disease;
- Download FULL TEXT /PDF 655 KB/
Please cite this article as:
Panov VE, Krasteva A, Krasteva AZ, Ivanova A, Panov A, Krastev Z. Azithromycin decrease saliva calprotectin in patients with periodontal diseases. J of IMAB. 2014 Jan-Jun;20(1):464-468. doi: 10.5272/jimab.2014201.464.
Correspondence to: Dr. Assya Krasteva, Department of Diagnostic Imaging and Oral diagnostic, Faculty of Dental Medicine, Medical University – Sofia; 1, G. Sofiyski blvd., Sofia, Bulgaria; E-mail: asyakrasteva@abv.bg
REFERENCES:
1. Becerik S, Afacan B, Oztürk VÖ, Atmaca H, Emingil G. Gingival crevicular fluid calprotectin, osteocalcin and cross-linked N-terminal telopeptid levels in health and different periodontal diseases. Dis Markers. 2011; 31(6):343-52. [PubMed] [CrossRef]
2. Blandizzi C, Malizia T, Lupetti A, Pesce D, Gabriele M, Giuca MR, et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol. 1999 Sep;70(9):960-6. [PubMed] [CrossRef]
3. Brandtzaeg P. Gabrielsen TO. Dale I. Müller F. Steinbakk M. Fagerhol MK. The leucocyte protein L1 (calprotectin): a putative nonspecific defence factor at epithelial surfaces. Adv Exp Med Biol. 1995; 371A:201-6. [PubMed]
4. Brun JG, Cuida M, Jacobsen H, Kloster R, Johannesen AC, Høyeraal HM, et al. Sjögren's syndrome in inflammatory rheumatic diseases: analysis of the leukocyte protein calprotectin in plasma and saliva. Scand J Rheumatol. 1994; 23(3):114-8. [PubMed]
5. Challacombe SJ. Immunologic aspects of oral candidiasis. Oral Surg Oral Med Oral Pathol. 1994 Aug; 78(2):202-10. [PubMed]
6. Challacombe SJ. Sweet SP. Salivary and mucosal immune responses to HIV and its co-pathogens. Oral Dis. 1997 May; 3 Suppl 1:S79-84. [PubMed]
7. Champaiboon C. Sappington KJ. Guenther BD. Ross KF. Herzberg MC. Calprotectin S100A9 calcium-binding loops I and II are essential for keratinocyte resistance to bacterial invasion. J Biol Chem. 2009 Mar 13;284(11):7078-90. [PubNed] [CrossRef]
8. Chen CC. Huang JL. Chang CJ. Kong MS. Fecal Calprotectin as a Correlative Marker in Clinical Severity of Infectious Diarrhea and Usefulness in Evaluating Bacterial or Viral Pathogens in Children. J Pediatr Gastroenterol Nutr. 2012 Nov;55(5):541-7. [PubMed] [CrossRef]
9. Cuida M. Brun JG. Tynning T. Jonsson R. Calprotectin levels in oral fluids: the importance of collection site. Eur J Oral Sci. 1995 Feb;103(1):8-10. [PubMed]
10. Cuida M. Halse AK. Johannessen AC. Tynning T. Jonsson R. Indicators of salivary gland inflammation in primary Sjogren's syndrome. Eur J Oral Sci. 1997 Jun;105(3):228-33. [PubMed]
11. Dawes C, Weatherell JA. Kinetics of fluoride in the oral fluids. J Dent Res. 69. 1990: 638–644. [PubMed]
12. Echelard S, Hoyaux D, Hermans M, Daelemans P, Roth J, Philippart P, et al. S100A8 and S100A9 calcium-binding proteins: localization within normal and cyclosporin A-induced overgrowth gingiva. Connect Tissue Res. 2002;43(2-3):419-24. [PubMed]
13. Gebhardt C. Németh J. Angel P. Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006 Nov 30;72(11):1622-31. [PubMed] [CrosRef]
14. Gomi K. Yashima A. Iino F. Kanazashi M. Nagano T. Shibukawa N. et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol. 2007 May;78(5):918-23. [PubMed] [CrossRef]
15. Heller F, Frischmann S, Grünbaum M, Zidek W, Westhoff TH. Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury. Clin J Am Soc Nephrol. 2011 Oct;6(10):2347-55. [PubMed] [CrossRef]
16. Idkaidek N. Arafat T. Saliva versus Plasma Pharmacokinetics: Theory and Application of a Salivary Excretion Classification System. Mol Pharm. 2012 Aug 6;9(8):2358-65. [PubMed] [CrossRef]
17. Javkhlan P. Hiroshima Y. Azlina A. Hasegawa T. Yao C. Akamatsu T. et al. Lipopolysaccharide-mediated induction of calprotectin in the submandibular and parotid glands of mice. Inflammation. 2011 Dec;34(6):668-80. [PubMed] [CrossRef]
18. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol. 1997 June; 50(3): 113–123. [PubMed]
19. Kharbanda AB. Rai AJ. Cosme Y. Liu K. Dayan PS. Novel serum and urine markers for pediatric appendicitis. Acad Emerg Med. 2012 Jan;19(1):56-62. [PubMed] [CrossRef]
20. Kleinegger CL. Stoeckel DC. Kurago ZB. A comparison of salivary calprotectin levels in subjects with and without oral candidiasis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jul;92(1):62-7. [PubMed] [CrossRef]
21. Krasteva, A. Whole unstimulated saliva as diagnostic tool for immunoinflammatory disease and oral neoplasm, PhD Dissertation, Sofia. 2009, p. 212. [in Bulgarian]
22. Malizia T. Tejada MR. Ghelardi E. Senesi S. Gabriele M. Giuca MR. et al. Periodontal tissue disposition of azithromycin. J Periodontol. 1997 Dec;68(12):1206-9. [PubMed] [CrossRef]
23. Müller F. Frøland SS. Brandtzaeg P. Fagerhol MK. Oral candidiasis is associated with low levels of parotid calprotectin in individuals with infection due to human immunodeficiency virus. Clin Infect Dis. 1993 Feb;16(2):301-2. [PubMed] [CrossRef]
24. Nakov V. Fecal calprotectin – non-invasive biomarker in intestinal inflammation assessment.
25. Ortega FJ, Sabater M, Moreno-Navarrete JM, Pueyo N, Botas P, Delgado E, et al. Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol. 2012 Oct;167(4):569-78. [PubMed] [CrossRef]
26. Ross KF. Herzberg MC. Calprotectin expression by gingival epithelial cells. Infect Immun. 2001 May; 69 (5):3248-54. [PubMed] [CrossRef]
27. Rutgeerts P. How to guide therapeutic decisions in a patient-tailored approach to treatment of IBD? Dig Dis. 2012;30(4):396-9. [PubMed] [CrossRef]
28. Saxer UP, Mühlemann HR. Motivation and education. [in German] SSO Schweiz Monatsschr Zahnheilkd. 1975 Sep;85(9):905-19. [PubMed]
29. Stríz I. Trebichavský I. Calprotectin - a pleiotropic molecule in acute and chronic inflammation. Physiol Res. 2004; 53(3):245-53. [PubMed]
30. Sweet SP. Denbury AN. Challacombe SJ. Salivary calprotectin levels are raised in patients with oral candidiasis or Sjögren's syndrome but decreased by HIV infection. Oral Microbiol Immunol. 2001 Apr;16(2):119-23. [PubMed] [CrossRef]
31. Toomarian L. Sattari M. Hashemi N. Tadayon N. Akbarzadeh Baghban A.Comparison of neutrophil apoptosis. α-defensins and calprotectin in children with and without severe early childhood caries. Iran J Immunol. 2011 Mar;8(1):11-19. [PubMed]
Received: 20 December 2013
Published online: 10 March 2014